Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma

NCT02004262 is registered in ClinicalTrials.gov with Aduro Biotech, Inc. as lead sponsor.

NCT NCT02004262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02004262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Aduro Biotech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 5, 2014
Completion date
August 23, 2016
Enrollment
303 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

2nd-line, 3rd-line and greater metastatic pancreatic cancer